ENDRA Life Sciences to Host Second Quarter 2019 Results Conference Call on Thursday, August 8, 2019 at 4:30 p.m. ET

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

ANN ARBOR, MI / ACCESSWIRE / July 22, 2019 / ENDRA Life Sciences Inc. (“ENDRA”) (NASDAQ: NDRA), a developer of enhanced ultrasound technologies, will hold a conference call on Thursday, August 8, 2019 at 4:30 p.m. Eastern time to discuss its results for the second quarter ended June 30, 2019. Financial results will be issued in a press release prior to the call.

ENDRA CEO Francois Michelon, CFO David Wells and CTO Michael Thornton will host the conference call, followed by a question and answer period.

To access the call, please use the following information:

Date:

Thursday, August 8, 2019

Time:

4:30 p.m. ET, 1:30 p.m. PT

Toll-free dial-in number:

844-602-0380

International dial-in number:

862-298-0970

Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact MZ Group at 1-949-491-8235.

The conference call will be broadcast live and available for replay at https://www.investornetwork.com/event/presentation/51307 and via the investor relations section of the Company’s website at www.endrainc.com.

A replay of the conference call will be available after 7:30 p.m. Eastern time through August 22, 2019.

Toll-free replay number:

877-481-4010

International replay number:

919-882-2331

Replay ID:

51307

About ENDRA Life Sciences Inc.

ENDRA Life Sciences Inc. (“ENDRA”) (NASDAQ: NDRA) is a developer of enhanced ultrasound technologies. ENDRA is developing a next generation Thermo-Acoustic Enhanced UltraSound (TAEUS) platform to enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only with CT & MRI – at a fraction of the cost, and at the point-of-care. ENDRA’s first TAEUS application will focus on the quantification of fat in the liver, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease (NAFLD). ENDRA’s goal is to bring new capabilities to ultrasound – thereby broadening access to better healthcare. For more information, please visit www.endrainc.com.

About Non-Alcoholic Fatty Liver Disease (NAFLD)

NAFLD is a condition closely associated with obesity, diabetes, hepatitis-C and certain genetic predispositions in which fat accumulates in the liver. NAFLD affects over 1 billion people globally and is estimated to cost the U.S healthcare system over $100 billion annually. NAFLD is often asymptomatic and if left untreated, NAFLD can progress to inflammation (NASH), tissue scarring (fibrosis), cell death (cirrhosis) and liver cancer. By 2025, NAFLD is forecast to be the greatest root cause of liver transplants. The only tools currently available for diagnosing and monitoring NAFLD are impractical: expensive Magnetic Resonance Imaging (MRI) or an invasive surgical biopsy.

Company Contact:

David Wells
Chief Financial Officer
(734) 997-0464
investors@endrainc.com
www.endrainc.com

Media & Investor Relations Contact:

MZ North America
Chris Tyson
Managing Director
(949) 491-8235
NDRA@mzgroup.us
www.mzgroup.us

SOURCE: ENDRA Life Sciences Inc.

View source version on accesswire.com:
https://www.accesswire.com/552810/ENDRA-Life-Sciences-to-Host-Second-Quarter-2019-Results-Conference-Call-on-Thursday-August-8-2019-at-430-pm-ET

user

Recent Posts

IDC Report: Huawei Ranks No.1 in Global Wrist-Worn Market in Q1

Huawei wearable devices Surpassed 200 Million Cumulative Shipments SHENZHEN, China, June 14, 2025 /PRNewswire/ -- According to…

2 hours ago

Decisely Notifies Individuals of Data Security Incident

ALPHARETTA, Ga., June 13, 2025 /PRNewswire/ -- Decisely learned of a data security incident that may…

14 hours ago

Abstractive Health Launches Clinical Time Machine, the First AI Game Built on Real Historical Patient Records

NEW YORK--(BUSINESS WIRE)--#digitalhealth--Abstractive Health has launched Clinical Time Machine, an AI-driven simulation that immerses physicians…

20 hours ago

The Berwyn Group Appoints Adam Wilson as General Manager of Healthcare

Veteran Leader Brings Deep Industry Expertise to Advance Berwyn's Healthcare Strategy INDEPENDENCE, Ohio, June 13,…

20 hours ago

Datalogic and B. Braun enable safer oncology treatment with Memor™ 17 Healthcare Certification for OncoSafety Remote Control®

BOLOGNA, Italy, June 13, 2025 /PRNewswire/ -- Datalogic, a global leader in the automatic data capture…

20 hours ago

Skypoint Launches Lia and Scribe: AI-Powered Agents Redefining Clinical Workflow Efficiency and Social Determinants of Health (SDOH) Data Capture

PORTLAND, Ore., June 13, 2025 /PRNewswire/ -- Skypoint, a leading provider of HITRUST r2-certified AI platform…

1 day ago